BioMelbourne Network Progressing BioIndustry

18th August BioBriefing - 'Investor Relations: The JP Morgan Annual Healthcare Conference Experience'
A discussion panel on a topic around the JP Healthcare Conference. More

BioMelbourne Network

The BioMelbourne Network is a membership based, industry forum representing business leaders in biotechnology, medical technology and innovation industries in Victoria. The power of our network resides with our members, who are some of the largest life sciences companies in Australia. Our mission is to support, connect and enable growth of our sector, through networking and professional development events that provide access to industry intelligence and promote peer-to-peer knowledge exchange.

Invion and Hovione Sign Joint Development and Licensing Agreement for Inhaled Zafirlukast

27 July 2015.  Australian drug development company Invion Limited (ASX: IVX)  has secured a commitment from Hovione Scientia Limited, an international pharmaceutical company expert in inhalation development and manufacturing, to progress development of inhaled INV104 (zafirlukast) as a potential new treatment for asthma.Invion and Hovione will collaborate to develop the proprietary novel techno... read more…

BioMelbourne Network - New Phone Number

We have a new phone number, please update your records and remove the old number.  BioMelbourne Network's new number is +61 (0)3 9667 8181 Nicole Pitcher Office Manager BioMelbourne Network Milton House, Level 2, 25 Flinders Lane Melbourne  Australia  3000 tel: +61 (0)3 9667 8181 mobile: +61 (0)409 182 900 email: npitcher@biomelbourne.org internet: www.biomelbourne.org   read more…

ARC Imaging Centre Work on Nanoparticles Published Today in Science

17 July 2015.  ARC Imaging Centre Work on Nanoparticles Published Today in Science. We are delighted to announce that our ARC Imaging Centre Associate Investigator Hans Elmlund's work on the structure of platinum nanoparticles has been published in Science today. Hans, a structural biologist at Monash University, worked with international colleagues including scientists at Berkeley, Princeton a... read more…

Gordagen Appoints Dr. Rocco Iannello as Director of Business Development

16 July 2015.  Gordagen Appoints Dr. Rocco Iannello as Director of Business Development. Gordagen Pharmaceuticals, a private biopharmaceutical and nutraceutical company developing tocotrienols, today announced the appointment of Dr. Rocco Iannello as Director of Business Development.Dr. Iannello will be responsible for Gordagen’s business development, including major international licensing a... read more…

MMV wins Tim Berners-Lee’s Open Data Innovation Award

14 July 2015.  Nominated by UK DFID, MMV chosen from a shortlist of 17 open data pioneers.MMV has won the Open Data Innovation Award, one of Five Open Data Awards presented by Tim Berners-Lee’s Open Data Institute (ODI) and hosted at Bloomberg London. The awards presented On Thursday, 9 July 2015, were in recognition of innovation and excellence in open data. MMV was one of 17 organizations sho... read more…

Global Biotech Industry Continues to Sizzle as Market Capitalization Surpasses US$1 Trillion

8 July 2015.  The global biotechnology industry reached new heights in 2014, setting records on virtually every major financial metric, including revenues, profitability and capital raised. These positive performance indicators, combined with several high-profile product successes and a strong year for new drug approvals, drove the industry’s total market capitalization above the US$1t threshol... read more…

BioMelbourne Network Announces Incoming Chair

8 July 2015.The BioMelbourne Network is pleased to announce that Mr Andrew Carter has been elected by the Board to succeed Mr Andrew Macdonald as Chair, effective from the 1st of July, 2015. Mr Andrew Macdonald has completed a distinguished period of service as Chair of the Network, following his appointment to the role in 2010. Andrew has provided strong leadership in overseeing the growth and... read more…

Nexvet and Zenoaq Enter Research and Development Collaboration

7 July 2015.  DUBLIN, Ireland, July 7, 2015 (GLOBE NEWSWIRE) -- Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer, today announced the signing of a research and development agreement with leading Japanese animal health company Zenoaq (Nippon Zenyaku Kogyo Co., Ltd.) to develop a number of therapeutic biologics for companion animals. The biologics will target undisclosed pro... read more…

Circadian Commences Wet AMD OPT-302 Clinical Trial

1 July 2015.  Circadian Technologies Limited (ASX:CIR, OTCQX:CKDXY) has commenced its Phase 1 study of OPT-302 in patients with wet age-related macular degeneration (wet AMD) following receipt of Institutional Review Board (IRB) approval and initiation of the five clinical trial sites in the US. The trial is under an investigational new drug (IND) authorisation received from the US Food and Dru... read more…

Invion Completes Dosing in Key Phase II Clinical Trial of Oral INV102 (NADOLOL) in Smoking Cessation

29 June 2015.  Invion Limited (ASX: IVX), an Australian drug development company, is pleased to announce that it   has completed dosing in INVSC001: “Efficacy and safety of beta-adrenoceptor inverse agonist, nadolol, in smoking cessation of patients with pre-existing COPD”.This double-blind, randomized, placebo-controlled Phase IIB clinical trial, is being performed in the United States under a... read more…

Medical Developments International Leads the Way with Pain-relief Drug

29 June 2015. For 15 years, Australian healthcare company Medical Developments International and the CSIRO have been working together to develop a unique invention that will benefit patients around the world. Finally, after an arduous process that involved going back to the start to create a new manufacturing method, a new non-addictive drug can be upscaled quickly, which will benefit patients ... read more…

Australian pain drug innovation company Spinifex Pharmaceuticals sold to Novartis for US$200m plus milestone payment

29 June 2015.  Spinifex Pharmaceuticals, Inc. and its Australian subsidiary Spinifex Pharmaceuticals Pty Ltd (“Spinifex”), a company focused on the development of new drugs for the treatment of chronic pain, today announced agreement to the sale of Spinifex to Novartis International AG (“Novartis”), for an upfront cash consideration of US$200 million plus significant further development and reg... read more…

Circadian receives IND approval from FDA to initiate clinical trial of OPT - 302 for wet AMD patients

15 June 2015.  Circadian Technologies Limited (ASX:CIR, OTCQX:CKDXY) through its wholly owned subsidiary Opthea Pty Ltd is pleased to announce that the US Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to initiate its Phase 1 clinical trial of OPT-302 in patients with wet age-related macular degeneration (wet AMD).Circadian’s CEO and Managing Dire... read more…

Tax Competitiveness for Advanced Manufacturing the key to commercialising Australian R&D

15 June 2015.  A more competitive corporate tax rate would enable Australia to attract valuable investment in advanced manufacturing and in turn convert its world leading R&D into fully-fledged industries located in Australia, according to CSL Limited, Australia’s largest biotechnology company. Australia has a skilled workforce, quality education and strong research base. These are the pillars... read more…

Antisense Therapeutics announces license deal with Sweden based Cortendo

12 June 2015.  Cortendo AB (publ) [ticker: CORT on NOTC-A], a biopharmaceutical company focused on rare endocrine disorders and other rare diseases, and Antisense Therapeutics Limited [ticker: ANP on ASX] today announced that the companies have entered into an exclusive license agreement that provides Cortendo with development and commercialization rights to Antisense Therapeutics’ ATL1103 for ... read more…

Commonwealth provides $10.6 million investment in projects for accelerating commercialisation

11 June 2015.  Eighteen Australian companies will receive grants to propel their innovative ideas from the drawing board into the marketplace under the Australian Government’s Accelerating Commercialisation programme.Industry and Science Minister Ian Macfarlane said the first round of $10.6 million in funding under the Accelerating Commercialisation element of the Australian Government’s $484.2... read more…

Design + Industry - "We’re Good Design Award Winners!"

10 June 2015.  The D+I team enjoyed another great night celebrating their design achievements at the 2015 Good Design Awards. With two prestigious Design Awards and three Design Selections they are thrilled with their winning results.Their work with Siemens Healthcare Diagnostics and Universal Biosensors for the Xprecia Stride™ Coagulation System won a Good Design Award in the Medical and Scien... read more…

LBT Begins Key U.S. Trial of APAS Technology

9 June 2015.  Australian medical technology company LBT Innovations Limited (ASX: LBT) has commenced the United States phase of the clinical trial programme for its pioneering culture-plate intelligent image analysis technology, APAS® (Automated Plate Assessment System). The trial now underway at TriCore Reference Laboratories in New Mexico is in support of LBT’s 510(k) de novo submission to t... read more…

Global Kinetics Corporation Closes $14.8 million Capital Raising

2 June 2015.  Australian health technology company Global Kinetics Corporation has successfully raised $14.8 million to rapidly progress the company’s global commercialisation strategy for its lead Parkinson’s KinetiGraph™ (PKG™) mobile health technology. Foundation investor Brandon Capital Partners has contributed further capital in the funding round. New investors include institutional inve... read more…

Aussie Hearing Invention Wins Coveted Awards

2 June 2015.  On May 29 2015, Good Design Australia presented Melbourne hearing device company Blamey Saunders hears with the inaugural Social Innovation award, in recognition of the IHearYou® system's role in creating a better society by removing barriers to quality hearing aids; barriers like cost, stigma and distance to service providers. Judges called it: “An innovation that not only has a ... read more…